AR118788A1 - Moléculas para terapia y diagnóstico - Google Patents
Moléculas para terapia y diagnósticoInfo
- Publication number
- AR118788A1 AR118788A1 ARP200101170A ARP200101170A AR118788A1 AR 118788 A1 AR118788 A1 AR 118788A1 AR P200101170 A ARP200101170 A AR P200101170A AR P200101170 A ARP200101170 A AR P200101170A AR 118788 A1 AR118788 A1 AR 118788A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- synuclein
- molecules
- lewy
- dementia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a moléculas que pueden emplearse para la prevención, el alivio, el tratamiento y/o el diagnóstico de enfermedades, trastornos y anormalidades asociadas con agregados de alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, A-sin, a-sin, aSin, a-sin), incluyendo, aunque sin limitaciones, cuerpos de Lewy y/o neuritas de Lewy, tales como enfermedad de Parkinson, atrofia sistémica múltiple, demencia de cuerpos de Lewy (LBD; demencia con cuerpos de Lewy (DLB) (demencia de cuerpos de Lewy pura), demencia de la enfermedad de Parkinson (PDD)) o enfermedad de cuerpos de Lewy difusos. La presente se refiere a moléculas de unión a alfa-sinucleína, en particular a anticuerpos de alfa-sinucleína o un fragmento de unión a antígeno o un derivado del mismo y a sus usos. Las presentes moléculas también se pueden usar para determinar una predisposición a dicho trastorno, enfermedad o anormalidad, para monitorear un trastorno, enfermedad o anormalidad residual, o para predecir la respuesta de un paciente que sufre de dicho trastorno, enfermedad o anormalidad al tratamiento con un determinado medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19170207 | 2019-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118788A1 true AR118788A1 (es) | 2021-11-03 |
Family
ID=66290208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101170A AR118788A1 (es) | 2019-04-18 | 2020-04-24 | Moléculas para terapia y diagnóstico |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118788A1 (es) |
-
2020
- 2020-04-24 AR ARP200101170A patent/AR118788A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068066A2 (pt) | compostos bicíclicos para diagnóstico e terapia | |
| Bordet et al. | Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report | |
| Lim et al. | Abnormal hippocampal neurogenesis in Parkinson’s disease: relevance to a new therapeutic target for depression with Parkinson’s disease | |
| Wang et al. | Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors | |
| Pereira Dias et al. | Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms | |
| Pinheiro et al. | Long-lasting recognition memory impairment and alterations in brain levels of cytokines and BDNF induced by maternal deprivation: effects of valproic acid and topiramate | |
| MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
| Brown et al. | Effects of chronic prednisone therapy on mood and memory | |
| Amidfar et al. | Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress | |
| MX2020012932A (es) | Nuevos compuestos para diagnostico. | |
| Chollet et al. | Serotonin selective reuptake inhibitors (SSRIs) and stroke | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| Cusin et al. | Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy | |
| Cahana-Amitay et al. | Psycholinguistics of aphasia pharmacotherapy: Asking the right questions | |
| Pain et al. | Neuroprotective effects of neuropeptide Y against neurodegenerative disease | |
| CL2023001580A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| Jang et al. | Seizure‐Induced Regulations of Amyloid‐β, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity | |
| Vila-Merkle et al. | Sex differences in amygdalohippocampal oscillations and neuronal activation in a rodent anxiety model and in response to infralimbic deep brain stimulation | |
| CL2019003903A1 (es) | Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo. | |
| Yan et al. | Transcutaneous vagus nerve stimulation: a new strategy for Alzheimer’s disease intervention through the brain-gut-microbiota axis? | |
| Byeon | The effect of computer based cognitive rehabilitation program on the improvement of generative naming in the elderly with mild dementia: preliminary study | |
| AR118788A1 (es) | Moléculas para terapia y diagnóstico | |
| WO2022093552A3 (en) | Rev-erb agonists | |
| Chouhan et al. | The ME7 prion model of neurodegeneration as a tool to understand and target neuroinflammation in Alzheimer’s disease | |
| Liu et al. | Dysfunction of the neurovascular unit in brain aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |